Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints

药效学 药代动力学 美罗培南 加药 医学 肾功能 药理学 人口 内科学 胃肠病学 泌尿科 抗生素 微生物学 生物 抗生素耐药性 环境卫生
作者
Sujata M. Bhavnani,Michael Trang,David C. Griffith,Olga Lomovskaya,Jeffrey Hammel,J. Loutit,Sue Cammarata,Michael N. Dudley,Paul G. Ambrose,Christopher M. Rubino
出处
期刊:Antimicrobial Agents and Chemotherapy [American Society for Microbiology]
卷期号:66 (12) 被引量:6
标识
DOI:10.1128/aac.02130-21
摘要

Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken using population pharmacokinetic models, nonclinical PK-PD targets for efficacy, in vitro surveillance data, and simulation to provide support for 2 g meropenem-2 g vaborbactam every 8 h (q8h) administered as a 3-h intravenous (i.v.) infusion, and dosing regimens adjusted for patients with renal impairment. Simulated patients varying by renal function measure (estimated glomerular filtration rate [eGFR], mL/min/1.73 m2 and absolute eGFR, mL/min) and resembling the clinical trial population (complicated urinary tract infection, including acute pyelonephritis) were generated. The PK-PD targets for meropenem, the percentage of time on day 1 that free-drug plasma concentrations were above the MIC (%T>MIC), and vaborbactam, the ratio of free-drug plasma area under the concentration-time curve (AUC) on day 1 to the MIC (AUC:MIC ratio), were calculated. Percent probabilities of achieving meropenem free-drug plasma %T>MIC and vaborbactam free-drug plasma AUC:MIC ratio targets were assessed. MIC distributions for Enterobacterales, KPC-producing Enterobacterales, and Pseudomonas aeruginosa were considered as part of an algorithm to assess PK-PD target attainment. For assessments of free-drug plasma PK-PD targets associated with a 1-log10 CFU reduction from baseline, percent probabilities of PK-PD target attainment ranged from 81.3 to 100% at meropenem-vaborbactam MIC values of 4 or 8 μg/mL among simulated patients. The results of these PK-PD target attainment analyses provide support for a dosing regimen of 2 g meropenem-2 g vaborbactam q8h administered as a 3-h i.v. infusion, with dosing regimens adjusted for patients with renal impairment and a meropenem-vaborbactam susceptibility breakpoint of ≤8 μg/mL (tested with a fixed vaborbactam concentration of 8 μg/mL) for Enterobacterales and P. aeruginosa based on these dosing regimens.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
万能图书馆应助完美冷安采纳,获得50
刚刚
1秒前
善学以致用应助精明的沅采纳,获得10
1秒前
Labubu发布了新的文献求助10
1秒前
2秒前
跑向wb完成签到,获得积分10
2秒前
凳凳子完成签到,获得积分10
2秒前
zgg完成签到,获得积分20
2秒前
3秒前
shinysparrow应助陈甸甸采纳,获得100
3秒前
shinn发布了新的文献求助10
4秒前
张美发布了新的文献求助10
4秒前
凡人完成签到,获得积分10
4秒前
调皮初蝶完成签到,获得积分10
4秒前
无花果应助林小不脏采纳,获得10
4秒前
CipherSage应助Rank采纳,获得10
4秒前
5秒前
赘婿应助活力青筠采纳,获得10
5秒前
wind完成签到,获得积分10
6秒前
7秒前
66发布了新的文献求助10
7秒前
大模型应助CHRIS采纳,获得10
8秒前
宋子琛发布了新的文献求助10
8秒前
小贤完成签到,获得积分20
9秒前
科研dog完成签到 ,获得积分10
10秒前
华健发布了新的文献求助10
10秒前
11秒前
fairyinn发布了新的文献求助20
11秒前
调皮初蝶发布了新的文献求助10
12秒前
难过千易发布了新的文献求助10
12秒前
完美冷安发布了新的文献求助50
12秒前
13秒前
drfwjuikesv应助66采纳,获得10
13秒前
鱼腩发布了新的文献求助10
15秒前
Serena完成签到,获得积分10
16秒前
马丝雨完成签到,获得积分10
16秒前
庸尘完成签到,获得积分10
17秒前
溯溯完成签到 ,获得积分10
18秒前
科研通AI2S应助华健采纳,获得10
19秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975375
求助须知:如何正确求助?哪些是违规求助? 3519700
关于积分的说明 11199305
捐赠科研通 3256034
什么是DOI,文献DOI怎么找? 1798049
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305